Protara Therapeutics Reports Q1 2026 Results, Advances TARA-002 Programs in LMs and NMIBC

Protara Therapeutics, Inc.

2026-Q1 EPS reported -$0.31

Cash and cash equivalents and investments of $177.4 million as of March 31, 2026, expected to fund operations into 2028.
Net loss of $17.8 million ($0.31 per share) for Q1 2026, compared to $11.9 million loss in Q1 2025.
Intends to submit BLA for TARA-002 in Lymphatic Malformations in second half of 2027 based on STARBORN-1 trial.
Expects to complete enrollment of BCG-Unresponsive cohort in ADVANCED-2 trial and initiate ADVANCED-3 trial in BCG-Naïve patients in second half of 2026.
Updated interim safety and durability data from STARBORN-1 to be presented at ISSVA World Congress in May 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Protara Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income $17.8 million, or $0.31 per share, EPS $0.31 per share.

Period: the first quarter ended March 31, 2026
Net income: $17.8 million, or $0.31 per share
EPS: $0.31 per share
Result: reported results

Exact text from the filing

For the first quarter of 2026, Protara incurred a net loss of $17.8 million, or $0.31 per share, compared with a net loss of $11.9 million, or $0.29 per share, for the same period in 2025.

View on SEC.gov

Browse all earnings releases →

Protara Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-055462

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.